WO2010009197A1 - Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use - Google Patents
Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use Download PDFInfo
- Publication number
- WO2010009197A1 WO2010009197A1 PCT/US2009/050636 US2009050636W WO2010009197A1 WO 2010009197 A1 WO2010009197 A1 WO 2010009197A1 US 2009050636 W US2009050636 W US 2009050636W WO 2010009197 A1 WO2010009197 A1 WO 2010009197A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloro
- ethoxybenzyl
- phenyl
- pyran
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2730931A CA2730931A1 (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
CN2009801279245A CN102112483A (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s, 3r, 4r, 5s, 6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3, 4, 5-triol and methods of their use |
KR1020117001024A KR101707246B1 (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
MX2011000503A MX2011000503A (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phe nyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use. |
JP2011518868A JP2011528366A (en) | 2008-07-17 | 2009-07-15 | (2S, 3R, 4R, 5S, 6R) -2- (4-Chloro-3- (4-ethoxybenzyl) phenyl) -6- (methylthio) tetrahydro-2H-pyran-3,4,5-triol Form and method of use |
RU2011105797/04A RU2505543C2 (en) | 2008-07-17 | 2009-07-15 | Solid forms (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzil)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods for their obtaining |
NZ590184A NZ590184A (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
AU2009270973A AU2009270973B2 (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl) -6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
UAA201101832A UA106048C2 (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s, 3r, 4r, 5s, 6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and use thereof |
BRPI0916191A BRPI0916191A2 (en) | 2008-07-17 | 2009-07-15 | SOLID FORMS OF (2S, 3R, 4R, 5S, 6R) -2-(4-CHLORO -3-(4-ETHOXYBENZYL) PHENYL) -6-(METHYTHYO) TETRAHYDRO-2H-PIRAN -3,4,5 - TRIOL AND METHODS OF ITS USE |
KR1020177001061A KR20170010069A (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
IL210269A IL210269A (en) | 2008-07-17 | 2010-12-26 | Crystalline forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3 (4 -ethoxybenzyl)phenyl)-6-(methylthio) tetrahydro-2h- pyran-3, 4, 5 -triol and pharmaceutical compositions comprising them |
ZA2011/00175A ZA201100175B (en) | 2008-07-17 | 2011-01-06 | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8142308P | 2008-07-17 | 2008-07-17 | |
US61/081,423 | 2008-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010009197A1 true WO2010009197A1 (en) | 2010-01-21 |
Family
ID=41137707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/050636 WO2010009197A1 (en) | 2008-07-17 | 2009-07-15 | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
Country Status (29)
Country | Link |
---|---|
US (2) | US8217156B2 (en) |
EP (1) | EP2332947B1 (en) |
JP (2) | JP2011528366A (en) |
KR (2) | KR101707246B1 (en) |
CN (2) | CN107629097A (en) |
AR (1) | AR072807A1 (en) |
AU (1) | AU2009270973B2 (en) |
BR (1) | BRPI0916191A2 (en) |
CA (1) | CA2730931A1 (en) |
CL (1) | CL2009001595A1 (en) |
CO (1) | CO6351797A2 (en) |
DK (1) | DK2332947T3 (en) |
ES (1) | ES2656357T3 (en) |
HK (1) | HK1243713A1 (en) |
HU (1) | HUE035400T2 (en) |
IL (1) | IL210269A (en) |
MX (1) | MX2011000503A (en) |
NO (1) | NO2332947T3 (en) |
NZ (1) | NZ590184A (en) |
PE (1) | PE20100260A1 (en) |
PL (1) | PL2332947T3 (en) |
PT (1) | PT2332947T (en) |
RU (1) | RU2505543C2 (en) |
SG (1) | SG185317A1 (en) |
TW (1) | TWI472521B (en) |
UA (1) | UA106048C2 (en) |
UY (1) | UY31992A (en) |
WO (1) | WO2010009197A1 (en) |
ZA (1) | ZA201100175B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109333A1 (en) * | 2010-03-02 | 2011-09-09 | Lexicon Pharmaceuticals, Inc. | 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
WO2012055169A1 (en) | 2010-10-27 | 2012-05-03 | 上海艾力斯医药科技有限公司 | C-arylglucoside derivative, preparation method therefor, and use thereof |
WO2012094293A1 (en) | 2011-01-05 | 2012-07-12 | Lexicon Pharmaceuticals, Inc. | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
WO2018067805A1 (en) | 2016-10-06 | 2018-04-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sotagliflozin |
WO2018073154A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
EP3466958A4 (en) * | 2016-05-25 | 2019-06-12 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | New crystal form of sodium-glucose co-transporter inhibitor medicine and preparation method and use thereof |
WO2019201752A1 (en) | 2018-04-17 | 2019-10-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EP3771718A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
JP2022533856A (en) * | 2019-07-05 | 2022-07-26 | 山東丹紅制薬有限公司 | Crystal forms of SGLT inhibitors and uses thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI499414B (en) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
KR101663324B1 (en) | 2007-07-26 | 2016-10-06 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
TWI472521B (en) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
DK2925735T3 (en) * | 2012-11-20 | 2019-06-17 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose co-transporter 1 |
WO2015058084A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
WO2015069441A1 (en) | 2013-10-18 | 2015-05-14 | Medivation Technologies, Inc. | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) |
KR102590696B1 (en) | 2015-07-30 | 2023-10-18 | 자이단호진 비세이부쯔 가가꾸 겡뀨까이 | Novel aminoglycoside antibiotic effective against multi-drug resistant bacteria |
CN110818722B (en) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | Three compounds, preparation method thereof and application thereof in synthesizing suogliflozin |
CA3113037A1 (en) * | 2018-09-26 | 2020-04-02 | Lexicon Pharmaceuticals, Inc. | Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis |
CN109824687B (en) * | 2019-03-26 | 2022-03-22 | 上海凌凯医药科技有限公司 | Novel synthetic method of xylofuranose derivative |
WO2022144465A1 (en) | 2021-01-04 | 2022-07-07 | Charité-Universitätsmedizin Berlin | Sotagliflozin for improving left atrial function |
WO2022155303A1 (en) | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
CN113880701A (en) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | Antidiabetic drug intermediate and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008042688A2 (en) * | 2006-09-29 | 2008-04-10 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
WO2009014970A1 (en) * | 2007-07-26 | 2009-01-29 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870699A (en) * | 1973-03-06 | 1975-03-11 | Upjohn Co | Lincomycin analogs |
WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
WO2006018150A1 (en) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituited cyclene, medicaments containing said compounds, use thereof and method for the production thereof |
ATE445608T1 (en) | 2005-02-23 | 2009-10-15 | Boehringer Ingelheim Int | GLUCOPYRANOSYL-SUBSTITUTED ((HETERO)ARYLETHYNYL-BENZYL)-BENZENE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER TYPE 2 (SGLT2) |
CN1820858A (en) * | 2006-03-10 | 2006-08-23 | 广西中医学院制药厂 | Multi-phase material spray method and device |
US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
TWI472521B (en) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
-
2009
- 2009-07-01 TW TW98122274A patent/TWI472521B/en active
- 2009-07-15 KR KR1020117001024A patent/KR101707246B1/en active IP Right Grant
- 2009-07-15 CA CA2730931A patent/CA2730931A1/en not_active Abandoned
- 2009-07-15 PL PL11155100T patent/PL2332947T3/en unknown
- 2009-07-15 KR KR1020177001061A patent/KR20170010069A/en not_active Application Discontinuation
- 2009-07-15 AU AU2009270973A patent/AU2009270973B2/en active Active
- 2009-07-15 SG SG2012077681A patent/SG185317A1/en unknown
- 2009-07-15 PT PT111551008T patent/PT2332947T/en unknown
- 2009-07-15 EP EP11155100.8A patent/EP2332947B1/en active Active
- 2009-07-15 CN CN201710477527.7A patent/CN107629097A/en not_active Withdrawn
- 2009-07-15 MX MX2011000503A patent/MX2011000503A/en active IP Right Grant
- 2009-07-15 NZ NZ590184A patent/NZ590184A/en unknown
- 2009-07-15 NO NO11155100A patent/NO2332947T3/no unknown
- 2009-07-15 DK DK11155100.8T patent/DK2332947T3/en active
- 2009-07-15 BR BRPI0916191A patent/BRPI0916191A2/en not_active Application Discontinuation
- 2009-07-15 RU RU2011105797/04A patent/RU2505543C2/en active
- 2009-07-15 UA UAA201101832A patent/UA106048C2/en unknown
- 2009-07-15 WO PCT/US2009/050636 patent/WO2010009197A1/en active Application Filing
- 2009-07-15 AR ARP090102685A patent/AR072807A1/en unknown
- 2009-07-15 CL CL2009001595A patent/CL2009001595A1/en unknown
- 2009-07-15 PE PE2009000944A patent/PE20100260A1/en not_active Application Discontinuation
- 2009-07-15 CN CN2009801279245A patent/CN102112483A/en active Pending
- 2009-07-15 JP JP2011518868A patent/JP2011528366A/en active Pending
- 2009-07-15 HU HUE11155100A patent/HUE035400T2/en unknown
- 2009-07-15 ES ES11155100.8T patent/ES2656357T3/en active Active
- 2009-07-15 US US12/503,225 patent/US8217156B2/en active Active
- 2009-07-16 UY UY0001031992A patent/UY31992A/en not_active Application Discontinuation
-
2010
- 2010-12-26 IL IL210269A patent/IL210269A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00175A patent/ZA201100175B/en unknown
- 2011-02-09 CO CO11014849A patent/CO6351797A2/en not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/530,645 patent/US9067962B2/en active Active
-
2015
- 2015-09-30 JP JP2015193990A patent/JP6283337B2/en active Active
-
2018
- 2018-03-02 HK HK18103068.1A patent/HK1243713A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008042688A2 (en) * | 2006-09-29 | 2008-04-10 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
WO2009014970A1 (en) * | 2007-07-26 | 2009-01-29 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
WO2011109333A1 (en) * | 2010-03-02 | 2011-09-09 | Lexicon Pharmaceuticals, Inc. | 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients |
TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
AU2011223861B2 (en) * | 2010-03-02 | 2015-07-23 | Lexicon Pharmaceuticals, Inc. | 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
WO2012004270A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012055169A1 (en) | 2010-10-27 | 2012-05-03 | 上海艾力斯医药科技有限公司 | C-arylglucoside derivative, preparation method therefor, and use thereof |
WO2012094293A1 (en) | 2011-01-05 | 2012-07-12 | Lexicon Pharmaceuticals, Inc. | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
JP2014501780A (en) * | 2011-01-05 | 2014-01-23 | レクシコン ファーマシューティカルズ インコーポレイテッド | Composition comprising an inhibitor of sodium-glucose symporter 1 and sodium-glucose symporter 2, and method of using the inhibitor |
JP2017105814A (en) * | 2011-01-05 | 2017-06-15 | レクシコン ファーマシューティカルズ インコーポレイテッド | Compositions comprising inhibitors of sodium-glucose cotransporters 1 and 2 and methods of using the inhibitors |
JP2019048866A (en) * | 2011-01-05 | 2019-03-28 | レクシコン ファーマシューティカルズ インコーポレイテッド | Compositions comprising inhibitors of sodium-glucose cotransporters 1 and 2 and use methods thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3466958A4 (en) * | 2016-05-25 | 2019-06-12 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | New crystal form of sodium-glucose co-transporter inhibitor medicine and preparation method and use thereof |
US10626135B2 (en) | 2016-05-25 | 2020-04-21 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof |
WO2018067805A1 (en) | 2016-10-06 | 2018-04-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sotagliflozin |
WO2018073154A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
WO2019201752A1 (en) | 2018-04-17 | 2019-10-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
JP2022533856A (en) * | 2019-07-05 | 2022-07-26 | 山東丹紅制薬有限公司 | Crystal forms of SGLT inhibitors and uses thereof |
JP7273997B2 (en) | 2019-07-05 | 2023-05-15 | 山東丹紅制薬有限公司 | Crystal forms of SGLT inhibitors and uses thereof |
EP3771718A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
WO2021019509A1 (en) | 2019-08-01 | 2021-02-04 | Lexicon Pharmaceuticals,Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
WO2021019507A1 (en) | 2019-08-01 | 2021-02-04 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
CN114258397A (en) * | 2019-08-01 | 2022-03-29 | 莱西肯医药有限公司 | Process for preparing crystalline form II soxhlet |
CN114269728A (en) * | 2019-08-01 | 2022-04-01 | 莱西肯医药有限公司 | Continuous process for preparing crystalline form II sogelliflozin |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2332947B1 (en) | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use | |
EP2183263B1 (en) | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors | |
KR101837488B1 (en) | Optically pure benzyl-4-chlorophenyl-c-glucoside derivative | |
EP3056507B1 (en) | C-aryl glucoside derivative, preparation method for same, and medical applications thereof | |
EP2488515A1 (en) | Process for the preparation of compounds useful as inhibitors of sglt2 | |
EP3404033B1 (en) | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | |
JP7160821B2 (en) | Novel glucose derivatives that are SGLT-2 inhibitors | |
JPH0232091A (en) | Novel aldphosphamide glycoside and its production and use | |
ES2638915T3 (en) | Method of preparing compounds used as SGLT-22 inhibitors | |
AU2013206276A1 (en) | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980127924.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09790436 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009270973 Country of ref document: AU Ref document number: 590184 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 210269 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2011518868 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/000503 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2730931 Country of ref document: CA Ref document number: 20117001024 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504/DELNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009270973 Country of ref document: AU Date of ref document: 20090715 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11014849 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009790436 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011105797 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0916191 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110117 |